We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,264

California Passes Two Drug Pricing Transparency Laws
  • Quarles & Brady LLP
  • USA
  • November 20 2017

Last month, California Governor Jerry Brown signed two new bills aimed at curtailing rising prescription drug costs, joining other states like


FDA Finalizes Policy for Sharing Patient-Specific Data from Medical Devices
  • Reed Smith LLP
  • USA
  • November 15 2017

FDA recently released guidance ("Manufacturers Sharing Patient-Specific Information from Medical Devices with Patients Upon Request") finalizing its


Three Years Later, Foley Survey Reveals Positive Prognosis for Telemedicine
  • Foley & Lardner LLP
  • USA
  • November 15 2017

When we launched Foley’s inaugural Telemedicine and Digital Health Survey in 2014, it was apparent that health care executives weren’t ready to make


2017 Telemedicine and Digital Health Survey
  • Foley & Lardner LLP
  • USA
  • November 15 2017

Fueled by surging demand among patients and providers, telemedicine is spreading rapidly throughout the health care system, according to the 2017


New Report Says Biosimilars Could Save $54 Billion in Biologics Spending
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • November 7 2017

According to a new report by RAND Corporation, biosimilars could save $54 billion in healthcare spending on biologics over the next ten years


CNN Investigates Expanding Use of Nuedexta in Nursing Homes
  • Stark & Stark
  • USA
  • October 16 2017

A recent investigation by CNN brought to light the expanding and allegedly inappropriate use of the prescription drug Nuedexta in nursing homes


Washington Healthcare Update - Sep 25, 2017
  • McGuireWoods LLP
  • USA
  • September 25 2017

On Sept. 20, the Congressional Diabetes Caucus Chairs Reps. Diana DeGette (D-CO) and Tom Reed (R-NY) sent a letter to FDA Commissioner Scott Gottlieb


California Governor Considers Drug Price Reporting Bill and Ban on Discounts and Rebates for Branded Pharmaceutical Products
  • Cooley LLP
  • USA
  • September 18 2017

The California State Legislature sent two new pharmaceutical pricing measures, S.B. 17 and A.B. 265, to Governor Jerry Brown on September 13th. S.B


How Companies Should Prep for Enforcement Shift to State AGs
  • Foley & Lardner LLP
  • USA
  • August 23 2017

“Top Cop” is how every state Attorney General wants to be known. In reality, state AGs have far more authority for civil enforcement than they do for


340B Update: Draft Executive Order Could Mean Changes to the 340B Program
  • K&L Gates
  • USA
  • July 13 2017

An early draft of the Trump administration’s proposed executive order (“EO”) on drug pricing issues could result in significant changes to the 340B